Log in to save to my catalogue

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necros...

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necros...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1ae676670dde47428b23d064b72c8265

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

About this item

Full title

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

Publisher

England: BioMed Central Ltd

Journal title

BMC gastroenterology, 2022-04, Vol.22 (1), p.199-12, Article 199

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

The effectiveness of ustekinumab (UST) in the treatment of Crohn's disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naïve and anti-TNF-exposed patients. Given the selective nature of pivotal trial designs, real-world effectiveness and safety studies are warranted. We report our experience...

Alternative Titles

Full title

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_1ae676670dde47428b23d064b72c8265

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1ae676670dde47428b23d064b72c8265

Other Identifiers

ISSN

1471-230X

E-ISSN

1471-230X

DOI

10.1186/s12876-022-02280-3

How to access this item